Gyre Therapeutics (GYRE) Non Operating Income (2010 - 2015)
Gyre Therapeutics (GYRE) posted quarterly Non Operating Income of $167000.0 for Q4 2022, up 4075.0% year-over-year from $4000.0 in Q4 2021, and down 40.99% quarter-over-quarter from $283000.0 in Q3 2022.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Non Operating Income (2010 - 2015) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Non Operating Income for 12 consecutive years, with $167000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Non Operating Income rose 4075.0% year-over-year to $167000.0; the TTM figure through Dec 2022 stood at $537000.0 (up 1276.92% YoY), while the FY2022 annual figure was $537000.0, up 1276.92% from the prior year.
- Non Operating Income retreated to $167000.0 in Q4 2022 per GYRE's latest filing, from $283000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $690000.0 in Q4 2018 and bottomed at $2000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $273450.0 across 5 years, with a median of $225000.0 in 2022.
- Annual changes were most pronounced in 2021 — Non Operating Income plunged 94.91% — and 2022, when it surged 4075.0%.
- Gyre Therapeutics' Non Operating Income stood at $690000.0 in 2018, then tumbled by 44.64% to $382000.0 in 2019, then sank by 93.46% to $25000.0 in 2020, then tumbled by 84.0% to $4000.0 in 2021, then soared by 4075.0% to $167000.0 in 2022.
- Business Quant data shows GYRE's Non Operating Income at $167000.0 in Q4 2022, $283000.0 in Q3 2022, and $85000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 681.32 Mn | 623.92 Mn | 26.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2015 | 61,000.00 |
| Mar 31, 2015 | 92,000.00 |
| Dec 31, 2014 | 119,000.00 |
| Sep 30, 2014 | 139,000.00 |
| Jun 30, 2014 | 148,000.00 |
| Mar 31, 2014 | 169,000.00 |
| Dec 31, 2013 | -51,000.00 |
| Sep 30, 2013 | 244,000.00 |
| Jun 30, 2013 | 117,000.00 |
| Mar 31, 2013 | 208,000.00 |
| Dec 31, 2012 | 289,000.00 |
| Sep 30, 2012 | 219,000.00 |
| Jun 30, 2012 | 258,000.00 |
| Mar 31, 2012 | 273,000.00 |
| Dec 31, 2011 | 340,000.00 |
| Sep 30, 2011 | 277,000.00 |
| Jun 30, 2011 | 314,000.00 |
| Mar 31, 2011 | 285,000.00 |
| Dec 31, 2010 | 324,000.00 |
| Sep 30, 2010 | 326,000.00 |